Abstract: A resonance massage method and device for massaging acupuncture points on the wrist, wherein the massage device is provided with two wave generators which are placed on the inner and outer wrist to output periodic waves in opposite directions, and the opposite periodic waves resonate to create resonance which is capable of persistently massaging the acupuncture points on the wrist.

Abstract: Systems and methods related to the field of cardiac resuscitation, and in particular to devices for assisting rescuers in performing cardio-pulmonary resuscitation (CPR) are described herein. In some aspects, a system and method can include obtaining values for depths of a plurality of the chest compressions and information about a physiological parameter of the person and providing periodic feedback to a user about chest compressions performed by the user based at least in part on the values for the depths of the plurality of the chest compressions and a target compression depth.

Abstract: A chest compression device includes a piston to apply compression to the sternum and incorporates leaf springs simultaneously driven by the piston to apply lateral compression to the thorax during chest compressions. A motor in the chest compression device provides motive power to cyclically extend and contract the piston to provide therapeutic chest compressions. One end of each leaf spring is operably connected to the piston and the other end of each leaf spring is secured to the backboard/base or to a support leg of the chest compression device such that during extension of the piston, each leaf spring is compressed against the device base or leg which causes the springs to flex and provide lateral compression of the patient's thorax in addition to the sternal compression of the piston.

Abstract: A moxibustion device includes a handle, a moxa stick clamping unit, a front fixing component, a front rolling ring, a front roller cover, a traditional Chinese medicine (moxa stick), a back roller cover, a back bearing, a back fixing component, a roller's inner screen and a rotary drum. The moxibustion device is of a more ergonomic design and allows for more accurate and more direct application of force and/or rolling on acupuncture points; it is applicable to the parts of body with a small bending scope such as joints of the limbs and cervical vertebra and large-area skin such as the waist and the back. It can be easily operated, and the acupuncture points and the main and collateral channels can be acutely located.

Abstract: The present invention refers to a multicompartment container configured to contain a medical solution. A first compartment is defined by a first peelable seal having a first length extension, L1, and a second peelable seal having a second length extension, L2. A second compartment is defined by the first peelable seal and a third peelable seal having a third length extension, L3. A third compartment is defined by the second and the third peelable seal. The first, second, and third peelable seals are joined and L1>L2+L3. The third compartment comprises a first angle, ?, between an inner side edge of the container and the third peelable seal ranging between 10°<?<80° and the first compartment comprises a second angle, ?, between the first and second peelable seals ranging between 20°<?<130°.

Abstract: A kit and method for compounding medicated treats for pet animals includes a first compound, a second compound, a mold assembly, and a blister pack subkit. The first compound includes an edible binding agent for the medicated treat. The second compound includes a nutritional supplement. The first compound and the second compound are admixed together with an auxiliary ingredient, which admixture is formed into the medicated treats using the mold assembly. The mold assembly includes at least a mold plate, a base plate, and a pair of mold clamps. The kit may also include an extractor to facilitate removal of medicated treats from the mold assembly. The blister pack subkit includes a blister pack for receiving the medicated treats, and an adhesive backing for sealing the medicated treats within the blister pack.

Abstract: There are described tooth filling materials and dental varnishes for inhibiting the biofilm formation of Streptococcus mutans containing (a) a quantity of an active substance for inhibiting the biofilm formation, (b) a material for forming a structure for the uptake and delayed release of the active substance and (c) a filling material system. Another aspect of this invention relates to a method for producing tooth filling materials or dental varnishes according to the invention for inhibiting the biofilm formation of Streptococcus mutans. The present invention also relates to a kit comprising tooth filling materials or dental varnishes according to the invention and one or more additional constituents. There are also described methods for inhibiting the biofilm formation of Streptococcus mutans, methods for producing a dental component which inhibits the biofilm formation and the use of the active substance for producing a dental material.

Abstract: Monolithic ceramic bodies that have a mixed-oxide marginal region and a metallic surface, where the ceramic body includes an oxide of a first metal (I), while the mixed-oxide marginal region includes the oxide of the first metal (I) and the oxide of a further metal (II) having a high affinity for oxygen, and the metallic surface includes the further metal (II). The mixed oxide marginal region includes a continuous concentration gradient of the first metal (I), from 100% in the core to 0% in the transitional region to the metallic surface of the ceramic body, and a continuous concentration gradient of the further metal (II), starting from 0% in the core to 100% in the transitional region to the metallic surface of the ceramic body, where the oxygen concentration in the mixed-oxide marginal region remains constant, and the monolithic structure of the ceramic body has no phase boundaries.

Abstract: The present invention discloses a dental restorative material comprising 10-50 mass % of (A) a polymerizable monomer, 5-80 mass % of (B) an organic-inorganic composite filler which is prepared by dispersing an inorganic fine filler having an average particle diameter of 1 ?m or smaller in an organic matrix and has an average particle diameter of 5.0-50 ?m, and 10-60 mass % of (C) a third component, i.e., an inorganic filler having an average particle diameter of 1.1-5.0 ?m, wherein the absolute value of the difference between the refractive index [nC] of the inorganic filler (C) and the refractive index [nB] of the organic-inorganic composite filler (B) (i.e., |nC?nB|) is 0.005-0.07 at 32° C. and the absolute value of the difference between the refractive index [nA] of the cured product of the polymerizable monomer (A) and the refractive index [nC] of the inorganic filler (C) (i.e., |nA?nC|) is 0.005-0.05 at 32° C.

Abstract: Dental compositions are described comprising an addition-fragmentation agent of the formula: wherein R1, R2 and R3 are each independently Zm-Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R1, R2 and R3 is Zm-Q-; Q is a linking group have a valence of m+1; Z is an ethylenically unsaturated polymerizable group; m is 1 to 6; each X1 is independently —O— or —NR4—, where R4 is H or C1-C4 alkyl; and n is 0 or 1. Also described are dental articles prepared from a dental composition comprising an addition-fragmentation agent and methods of treating a tooth surface.

Abstract: The invention relates to a dental restorative material which comprises a thermolabile compound of Formula I: [(Z1)m-Q1-X)]k-T-[Y-Q2-(Z2)n]l??Formula I, in which T represents a thermolabile unit which contains at least one thermolabile group based on non-covalent interactions, Z1 and Z2 in each case independently represent a polymerizable group selected from vinyl groups, CH2?CR1—CO—O— and CH2?CR1—CO—NR2— or an adhesive group selected from —Si(OR)3, —COOH, —O—PO(OH)2, —PO(OH)2, —SO2OH and —SH, Q1 in each case independently is missing or represents an (m+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, Q2 in each case independently is missing or represents an (n+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, X and Y in each case independently are missing or represent —O—, —

Abstract: A pigmented skin care composition including a dermatologically acceptable carrier and at least a first and second interference pigment. The composition according to the invention is useful in improving the appearance of the skin and in particular in reducing the appearance of skin discontinuities.

Abstract: The present invention relates to improved powderous formulations of organic acids or esters having an aromatic ring system, as well as to the production of such formulations.

Abstract: The present invention relates to a composition comprising a mixture of: hydrophobic silica aerogel particles with a specific surface area per unit of mass (SM) ranging from 500 to 1500 m2/g and a size expressed as the mean volume diameter (D[0.5]) ranging from 1 to 1500 ?m, and at least a first and at least a second hydrocarbon-based oil chosen from branched esters, pentacrythritol esters, hydrogenated polyolefins and fatty acid triglycerides, and mixtures thereof, the first hydrocarbon-based oil being present in a content of greater than or equal to 40% by weight of the mixture of the first and second oils.

Abstract: An encapsulated oral care composition includes: (a) a gelatin capsule; and (b) a oral care composition contained within the capsule, and including: (i) a hydrophilic active; (ii) a hydrophobic structuring agent; and (iii) an oil carrier. The hydrophilic active is preferably cetylpyridinium chloride. The hydrophobic structuring agent is preferably a gelled mineral oil. The oil carrier is preferably a vegetable oil. A method of cleaning teeth includes applying to the teeth the encapsulated oral care composition such that the capsule releases the oral care composition to clean the teeth. A oral care implement includes: a handle; a head mounted to the handle, the head having an outer surface and a plurality of tooth cleaning elements extending outwardly from the outer surface; and the encapsulated oral care composition positioned on the head.

Abstract: Described herein are stable aqueous stannous ion containing compositions and methods of preparing and using the same.

Abstract: Compositions and methods for forming, in an aqueous environment, a nanoaggregate of calcium fluoride and amorphous calcium phosphate-containing compound, such as amorphous calcium phosphate fluoride or amorphous calcium carbonate phosphate fluoride are described. The nanoaggregate (or nanocomposite) can release calcium, phosphate, and fluoride, and ultimately convert to the tooth mineral, fluorapatite. One method for forming such a nanoaggregate involves applying a non-aqueous (e.g., varnish-based) composition (e.g., a suspension), containing solid particles of water soluble salts of calcium, phosphate, and fluoride, to the aqueous environment of the mouth. This results in rapid solubilization of the salts, precipitation of the nanoaggregate, and tooth remineralization. Tooth fluoridation and remineralization may also be carried out by applying to the tooth a non-aqueous carrier containing the nanoaggregate. Whitening agents can also be added to these compositions and methods.

Abstract: The present invention relates to the cosmetic use of at least one C4-C16 glycol with a hydrocarbon-chain and/or of a hydroxylated ester resulting from the esterification of polyol and/or of C4-C16 carboxylic acid(s), in a composition for caring for and/or making up the skin and/or the lips, as an agent for reinforcing the natural flesh tint of the skin and/or the lips and/or the natural volume of the lips.

Abstract: The present invention relates to a process for treating straightened keratin fibers, in which a composition comprising at least one carboxylic acid in its acid or salified form, the pH being greater than 8, is applied to the straightened keratin fibers.

Abstract: A method of treating a material, the method comprising the steps of: (i) contacting the material with a coloring composition comprising a dye compound; and (ii) contacting the material with a composition comprising a quaternary ammonium salt.

Abstract: Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.

Abstract: The invention relates to compositions which can be used for preparing structured formulations, to structured formulations comprising these compositions, and to processes for the preparation of structured formulations.

Abstract: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory pep tides in a topical formulation. Preferred octapeptide sequences are internally rich in tryptophan and/or tyrosine or arginine. The present invention is further directed to kits and compositions containing the present peptides, and methods of treatment of conditions involving expression of tyrosinase, in which the present peptides are administered topically for the treatment of conditions involving melanocyte activity in the skin.

Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.

Abstract: The present invention relates to a cosmetic composition comprising a latex film forming polymer, an acid, water and optionally a pigment, said composition having a pH of from about 6.5 to about 8. The invention also relates to a method for making up and/or enhancing the appearance of a keratinous substrate, in particular lashes, by applying these compositions to the keratinous substrate.

Abstract: A sun-care composition having an SPF value of at least (15) containing (a) one or more sun-care actives; (b) a copolymer (or a terpolymer) containing (A) at least one vinyl pyrrolidone monomer and (i) at least one vinyl caprolactam monomer or (ii) at least one vinyl acetate monomer or (B) at least one vinyl caprolactam monomer and at least one vinyl acetate monomer; and (c) a pharmaceutically/cosmetically/dermatologically acceptable vehicle.

Abstract: Disclosed are compositions and method for their use comprising effective amount of Silybum marianum extract and Momordica grosvenori fruit extract.

Abstract: The invention relates to an extract of cotton fibers, a cosmetic composition comprising, by way of an active principle, at least one extract of cotton fibers, formed by mono, di, tri and tetra saccharides, in a physiologically suitable medium. The invention also relates to a cosmetic treatment method for protecting keratin substrates, for reinforcing the skin's cutaneous barrier and/or for reinforcing protection of the hair and/or for enhancing keratin synthesis and/or for nourishing keratin substrates. The invention also relates to a method for producing an extract of cotton fibers and to the use thereof for the preparation of a cosmetic composition according to the invention.

Abstract: In certain embodiments, the invention is directed to a formulation for providing skin tightening which includes two or more of the following agents: red split lentils, Multani Mitti, charoli, chandan powder, and turmeric powder. Two or more of the agents can be ground and combined together in an effective amount. The combined agents can be additionally combined with a topical excipient.

Abstract: This invention relates to foamable compositions that are capable of producing a sensation or sensation modifying effect upon application on a body surface. More particularly the invention relates to foamable pharmaceutical, therapeutic and cosmetic compositions, comprising an active agent, having a sensation or sensation modifying affect on a body surface, upon application. More particularly, the invention relates to foamable compositions comprising: (a) a foamable carrier; (b) at least one sensation or sensation modifying agent, selected from the group of a cooling agent; a warming agent; a relaxing or soothing agent; stimulating or refreshing agent; or mixtures thereof and (c) a propellant at a concentration of about 3% to about 45% by weight of the total composition. The foamable carrier can be an emollient emulsion foamable vehicle, a foamable gel vehicle and can also be a substantially non aqueous foamable vehicle.

Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein: and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioral disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioral disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.

Abstract: Described is a medically useful article comprising a three-dimensional body including one or more implantable substances, wherein the body defines one or more reservoirs for receiving amounts of a biocompatible wetting liquid. In certain embodiments the body is disruptable upon wetting with the biocompatible liquid to form a conformable implantable material such as a putty, paste or more flowable wetted implant material. Also described are methods for manufacturing such medical materials, and methods for using such medical materials to treat patients.

Abstract: The invention provides compositions and methods for achieving storage stable aceclidine. The compositions preferably comprise aceclidine, a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. The invention further provides methods for treating refractive errors of the eye with a storage stable aceclidine composition.

Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

Abstract: The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

Abstract: The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet (1) longer in one direction when seen in plan. The tablet (1) has side edges (6) each of which extends in a longitudinal direction and is formed in the shape of a curve projecting outwardly in plan view. The curve has a radius of curvature (R1) set to at least 1.5 times a length (L) of the tablet. This makes a projected area of the tablet (1) in plan view at least 97% with respect to a projected area of a standard elliptical tablet having opposite end portions each of which is formed by a semi-circle having a diameter of a width (W) of the tablet.

Abstract: The present invention provides, compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material. In various embodiments, the matrix material is suitable for routine use. The compressible absorbent matrix material has a size, shape and/or geometry configured for efficient packing into a small space, and/or configured to absorb and substantially retain digested material in the stomach. The devices and compositions may further comprise one or more hydrogel(s), soluble or insoluble fibers, waxes and/or gums to provide the desired mechanical properties and/or absorptive or shielding properties.

Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.

Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Abstract: A pharmaceutical composition in multilayer-coated form including an omega-3 fatty acid or an alkyl ester thereof and a statin-based drug, and more particularly, a pharmaceutical composition for oral administration including: (a) a gelatin capsule core containing an omega-3 fatty acid or an alkyl ester thereof; (b) a first coating layer formed by coating, on the gelatin capsule core, hydroxypropyl methylcellulose and a copolymer of butyl methacrylate, (2-demethylaminoeethyl) methacrylate, and methyl methacrylate at a weight ratio of 1:2:1; and (c) a second coating layer formed by coating, on the first coating layer, a coating solution containing a statin-based drug.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: A therapeutic system, designed as a laminate and including at least one adhesive laminate layer is described. Also described is a therapeutic device having such a therapeutic system. For this purpose, at least one laminate layer or one intermediate layer and/or one intermediate layer arranged between two laminate layers contains superparamagnetic nanoparticles. The therapeutic device having such a therapeutic system includes at least one electrically controllable system which is detachably connected to the therapeutic system. The electrically controllable system has a frequency-dependent electric resistance. During operation of the therapeutic device, the electrically controllable system generates an electric or magnetic field, which can be varied in orientation and intensity over time and penetrates the superparamagnetic nanoparticles. This provides a controllable therapeutic system that is independent of contact surfaces, and a therapeutic device having such a controllable therapeutic system.

Abstract: A mucoadhesive patch that consists of an adhesive layer and a backing layer, wherein the adhesive layer contains a nonionic and an anionic hydrocolloid in a weight ratio of 1:2 to 1:5, and the backing layer contains a matrix of a nonionic and an anionic hydrocolloid in a weight ratio of 2:1 to 5:1.

Abstract: Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to cancer chemotherapeutic agents that are degraded by ALD3H1. The compositions described herein act as competitive inhibitors of ALD3H1 and thereby reduce breakdown of chemotherapeutics by this enzyme, and increase their efficacy for cancer treatment.

Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

Abstract: A method of improving cognition in a patient with Down syndrome, which entails administering one or more ?2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.